nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—HTR2B—Sorafenib—thyroid cancer	0.362	0.476	CbGbCtD
Agomelatine—HTR2C—Sorafenib—thyroid cancer	0.235	0.31	CbGbCtD
Agomelatine—CYP1A2—Sorafenib—thyroid cancer	0.0856	0.113	CbGbCtD
Agomelatine—CYP2C9—Sorafenib—thyroid cancer	0.0771	0.102	CbGbCtD
Agomelatine—Nasopharyngitis—Vandetanib—thyroid cancer	0.00366	0.0207	CcSEcCtD
Agomelatine—Influenza—Vandetanib—thyroid cancer	0.00354	0.02	CcSEcCtD
Agomelatine—Weight decreased—Vandetanib—thyroid cancer	0.0032	0.0181	CcSEcCtD
Agomelatine—Infestation NOS—Vandetanib—thyroid cancer	0.00315	0.0178	CcSEcCtD
Agomelatine—Infestation—Vandetanib—thyroid cancer	0.00315	0.0178	CcSEcCtD
Agomelatine—Depression—Vandetanib—thyroid cancer	0.00314	0.0178	CcSEcCtD
Agomelatine—Eczema—Sorafenib—thyroid cancer	0.00307	0.0174	CcSEcCtD
Agomelatine—Hepatic failure—Sorafenib—thyroid cancer	0.00307	0.0174	CcSEcCtD
Agomelatine—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00298	0.0169	CcSEcCtD
Agomelatine—Nabumetone—PTGS2—thyroid cancer	0.00295	0.367	CrCbGaD
Agomelatine—Eye disorder—Vandetanib—thyroid cancer	0.00264	0.0149	CcSEcCtD
Agomelatine—Indomethacin—PPARG—thyroid cancer	0.00262	0.326	CrCbGaD
Agomelatine—Mental disorder—Vandetanib—thyroid cancer	0.00248	0.014	CcSEcCtD
Agomelatine—Nasopharyngitis—Sorafenib—thyroid cancer	0.00247	0.0139	CcSEcCtD
Agomelatine—Vision blurred—Vandetanib—thyroid cancer	0.00232	0.0131	CcSEcCtD
Agomelatine—Tremor—Vandetanib—thyroid cancer	0.00231	0.013	CcSEcCtD
Agomelatine—Weight decreased—Sorafenib—thyroid cancer	0.00216	0.0122	CcSEcCtD
Agomelatine—Infestation NOS—Sorafenib—thyroid cancer	0.00213	0.012	CcSEcCtD
Agomelatine—Infestation—Sorafenib—thyroid cancer	0.00213	0.012	CcSEcCtD
Agomelatine—Anxiety—Vandetanib—thyroid cancer	0.00209	0.0118	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00208	0.0118	CcSEcCtD
Agomelatine—Jaundice—Sorafenib—thyroid cancer	0.00207	0.0117	CcSEcCtD
Agomelatine—Dry mouth—Vandetanib—thyroid cancer	0.00205	0.0116	CcSEcCtD
Agomelatine—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00201	0.0114	CcSEcCtD
Agomelatine—Infection—Vandetanib—thyroid cancer	0.002	0.0113	CcSEcCtD
Agomelatine—Nervous system disorder—Vandetanib—thyroid cancer	0.00197	0.0111	CcSEcCtD
Agomelatine—Skin disorder—Vandetanib—thyroid cancer	0.00195	0.011	CcSEcCtD
Agomelatine—Connective tissue disorder—Sorafenib—thyroid cancer	0.00188	0.0106	CcSEcCtD
Agomelatine—Rash erythematous—Epirubicin—thyroid cancer	0.00183	0.0104	CcSEcCtD
Agomelatine—Insomnia—Vandetanib—thyroid cancer	0.00182	0.0103	CcSEcCtD
Agomelatine—Paraesthesia—Vandetanib—thyroid cancer	0.00181	0.0102	CcSEcCtD
Agomelatine—Tinnitus—Sorafenib—thyroid cancer	0.00178	0.0101	CcSEcCtD
Agomelatine—Dyspepsia—Vandetanib—thyroid cancer	0.00177	0.01	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00174	0.00981	CcSEcCtD
Agomelatine—Fatigue—Vandetanib—thyroid cancer	0.00173	0.0098	CcSEcCtD
Agomelatine—Constipation—Vandetanib—thyroid cancer	0.00172	0.00972	CcSEcCtD
Agomelatine—Rash erythematous—Doxorubicin—thyroid cancer	0.0017	0.00959	CcSEcCtD
Agomelatine—Mental disorder—Sorafenib—thyroid cancer	0.00167	0.00945	CcSEcCtD
Agomelatine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00164	0.00929	CcSEcCtD
Agomelatine—Abdominal pain—Vandetanib—thyroid cancer	0.00159	0.00898	CcSEcCtD
Agomelatine—Angioedema—Sorafenib—thyroid cancer	0.00152	0.00858	CcSEcCtD
Agomelatine—Asthenia—Vandetanib—thyroid cancer	0.00144	0.00815	CcSEcCtD
Agomelatine—Pruritus—Vandetanib—thyroid cancer	0.00142	0.00804	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.0014	0.00794	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.0014	0.00794	CcSEcCtD
Agomelatine—Abnormal dreams—Epirubicin—thyroid cancer	0.00139	0.00785	CcSEcCtD
Agomelatine—Dry mouth—Sorafenib—thyroid cancer	0.00138	0.00782	CcSEcCtD
Agomelatine—Diarrhoea—Vandetanib—thyroid cancer	0.00138	0.00777	CcSEcCtD
Agomelatine—Naproxen—PTGS2—thyroid cancer	0.00137	0.17	CrCbGaD
Agomelatine—Infection—Sorafenib—thyroid cancer	0.00135	0.00762	CcSEcCtD
Agomelatine—Nervous system disorder—Sorafenib—thyroid cancer	0.00133	0.00752	CcSEcCtD
Agomelatine—Dizziness—Vandetanib—thyroid cancer	0.00133	0.00751	CcSEcCtD
Agomelatine—Skin disorder—Sorafenib—thyroid cancer	0.00132	0.00745	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.0013	0.00735	CcSEcCtD
Agomelatine—Abnormal dreams—Doxorubicin—thyroid cancer	0.00128	0.00726	CcSEcCtD
Agomelatine—Vomiting—Vandetanib—thyroid cancer	0.00128	0.00723	CcSEcCtD
Agomelatine—Headache—Vandetanib—thyroid cancer	0.00126	0.00712	CcSEcCtD
Agomelatine—Nausea—Vandetanib—thyroid cancer	0.00119	0.00675	CcSEcCtD
Agomelatine—Dyspepsia—Sorafenib—thyroid cancer	0.00119	0.00675	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00117	0.00663	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00117	0.00662	CcSEcCtD
Agomelatine—Fatigue—Sorafenib—thyroid cancer	0.00117	0.00661	CcSEcCtD
Agomelatine—Constipation—Sorafenib—thyroid cancer	0.00116	0.00656	CcSEcCtD
Agomelatine—Hepatic failure—Epirubicin—thyroid cancer	0.00113	0.00641	CcSEcCtD
Agomelatine—Eczema—Epirubicin—thyroid cancer	0.00113	0.00641	CcSEcCtD
Agomelatine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00111	0.00627	CcSEcCtD
Agomelatine—Indomethacin—PTGS2—thyroid cancer	0.00111	0.138	CrCbGaD
Agomelatine—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.00108	0.00613	CcSEcCtD
Agomelatine—Urticaria—Sorafenib—thyroid cancer	0.00108	0.00609	CcSEcCtD
Agomelatine—Abdominal pain—Sorafenib—thyroid cancer	0.00107	0.00606	CcSEcCtD
Agomelatine—Hepatic failure—Doxorubicin—thyroid cancer	0.00105	0.00593	CcSEcCtD
Agomelatine—Eczema—Doxorubicin—thyroid cancer	0.00105	0.00593	CcSEcCtD
Agomelatine—Migraine—Epirubicin—thyroid cancer	0.001	0.00567	CcSEcCtD
Agomelatine—Face oedema—Epirubicin—thyroid cancer	0.000984	0.00556	CcSEcCtD
Agomelatine—Asthenia—Sorafenib—thyroid cancer	0.000973	0.0055	CcSEcCtD
Agomelatine—Pruritus—Sorafenib—thyroid cancer	0.000959	0.00542	CcSEcCtD
Agomelatine—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000939	0.0169	CbGpPWpGaD
Agomelatine—MTNR1A—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000936	0.0169	CbGpPWpGaD
Agomelatine—MTNR1B—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000936	0.0169	CbGpPWpGaD
Agomelatine—Migraine—Doxorubicin—thyroid cancer	0.000929	0.00525	CcSEcCtD
Agomelatine—Diarrhoea—Sorafenib—thyroid cancer	0.000928	0.00524	CcSEcCtD
Agomelatine—MTNR1B—G alpha (i) signalling events—SST—thyroid cancer	0.000915	0.0165	CbGpPWpGaD
Agomelatine—MTNR1A—G alpha (i) signalling events—SST—thyroid cancer	0.000915	0.0165	CbGpPWpGaD
Agomelatine—Nasopharyngitis—Epirubicin—thyroid cancer	0.000912	0.00515	CcSEcCtD
Agomelatine—Face oedema—Doxorubicin—thyroid cancer	0.000911	0.00515	CcSEcCtD
Agomelatine—Dizziness—Sorafenib—thyroid cancer	0.000897	0.00507	CcSEcCtD
Agomelatine—Influenza—Epirubicin—thyroid cancer	0.000881	0.00498	CcSEcCtD
Agomelatine—MTNR1B—GPCR downstream signaling—CALCB—thyroid cancer	0.00087	0.0157	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—CALCB—thyroid cancer	0.00087	0.0157	CbGpPWpGaD
Agomelatine—Vomiting—Sorafenib—thyroid cancer	0.000862	0.00487	CcSEcCtD
Agomelatine—Headache—Sorafenib—thyroid cancer	0.00085	0.0048	CcSEcCtD
Agomelatine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000844	0.00477	CcSEcCtD
Agomelatine—Influenza—Doxorubicin—thyroid cancer	0.000815	0.00461	CcSEcCtD
Agomelatine—Nausea—Sorafenib—thyroid cancer	0.000805	0.00455	CcSEcCtD
Agomelatine—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000803	0.0145	CbGpPWpGaD
Agomelatine—Weight increased—Epirubicin—thyroid cancer	0.000802	0.00453	CcSEcCtD
Agomelatine—Weight decreased—Epirubicin—thyroid cancer	0.000797	0.00451	CcSEcCtD
Agomelatine—MTNR1B—Signaling by GPCR—CALCB—thyroid cancer	0.00079	0.0143	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—CALCB—thyroid cancer	0.00079	0.0143	CbGpPWpGaD
Agomelatine—Infestation NOS—Epirubicin—thyroid cancer	0.000786	0.00444	CcSEcCtD
Agomelatine—Infestation—Epirubicin—thyroid cancer	0.000786	0.00444	CcSEcCtD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.000785	0.0142	CbGpPWpGaD
Agomelatine—Jaundice—Epirubicin—thyroid cancer	0.000766	0.00433	CcSEcCtD
Agomelatine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000743	0.0042	CcSEcCtD
Agomelatine—Weight increased—Doxorubicin—thyroid cancer	0.000742	0.00419	CcSEcCtD
Agomelatine—Weight decreased—Doxorubicin—thyroid cancer	0.000738	0.00417	CcSEcCtD
Agomelatine—MTNR1B—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000728	0.0131	CbGpPWpGaD
Agomelatine—MTNR1A—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000728	0.0131	CbGpPWpGaD
Agomelatine—Infestation—Doxorubicin—thyroid cancer	0.000727	0.00411	CcSEcCtD
Agomelatine—Infestation NOS—Doxorubicin—thyroid cancer	0.000727	0.00411	CcSEcCtD
Agomelatine—MTNR1A—GPCR ligand binding—TSHR—thyroid cancer	0.000713	0.0129	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—TSHR—thyroid cancer	0.000713	0.0129	CbGpPWpGaD
Agomelatine—Jaundice—Doxorubicin—thyroid cancer	0.000709	0.00401	CcSEcCtD
Agomelatine—Hepatitis—Epirubicin—thyroid cancer	0.000705	0.00399	CcSEcCtD
Agomelatine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000693	0.00392	CcSEcCtD
Agomelatine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000688	0.00389	CcSEcCtD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—NRAS—thyroid cancer	0.000663	0.012	CbGpPWpGaD
Agomelatine—Eye disorder—Epirubicin—thyroid cancer	0.000659	0.00373	CcSEcCtD
Agomelatine—Tinnitus—Epirubicin—thyroid cancer	0.000658	0.00372	CcSEcCtD
Agomelatine—Hepatitis—Doxorubicin—thyroid cancer	0.000653	0.00369	CcSEcCtD
Agomelatine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000641	0.00363	CcSEcCtD
Agomelatine—Mental disorder—Epirubicin—thyroid cancer	0.000618	0.00349	CcSEcCtD
Agomelatine—Eye disorder—Doxorubicin—thyroid cancer	0.00061	0.00345	CcSEcCtD
Agomelatine—Tinnitus—Doxorubicin—thyroid cancer	0.000609	0.00344	CcSEcCtD
Agomelatine—MTNR1A—GPCR ligand binding—PTCH1—thyroid cancer	0.000606	0.0109	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—PTCH1—thyroid cancer	0.000606	0.0109	CbGpPWpGaD
Agomelatine—Back pain—Epirubicin—thyroid cancer	0.000594	0.00336	CcSEcCtD
Agomelatine—Vision blurred—Epirubicin—thyroid cancer	0.000579	0.00327	CcSEcCtD
Agomelatine—Mental disorder—Doxorubicin—thyroid cancer	0.000572	0.00323	CcSEcCtD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—KRAS—thyroid cancer	0.000571	0.0103	CbGpPWpGaD
Agomelatine—Agitation—Epirubicin—thyroid cancer	0.000564	0.00319	CcSEcCtD
Agomelatine—MTNR1B—GPCR ligand binding—SST—thyroid cancer	0.000554	0.01	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—SST—thyroid cancer	0.000554	0.01	CbGpPWpGaD
Agomelatine—Vertigo—Epirubicin—thyroid cancer	0.000552	0.00312	CcSEcCtD
Agomelatine—Back pain—Doxorubicin—thyroid cancer	0.00055	0.00311	CcSEcCtD
Agomelatine—Vision blurred—Doxorubicin—thyroid cancer	0.000535	0.00303	CcSEcCtD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—NRAS—thyroid cancer	0.000535	0.00965	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—CALCA—thyroid cancer	0.000533	0.00962	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—CALCA—thyroid cancer	0.000533	0.00962	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—PPARG—thyroid cancer	0.00053	0.00956	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—PPARG—thyroid cancer	0.00053	0.00956	CbGpPWpGaD
Agomelatine—Agitation—Doxorubicin—thyroid cancer	0.000522	0.00295	CcSEcCtD
Agomelatine—Anxiety—Epirubicin—thyroid cancer	0.000521	0.00294	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000519	0.00293	CcSEcCtD
Agomelatine—Dry mouth—Epirubicin—thyroid cancer	0.000511	0.00289	CcSEcCtD
Agomelatine—Vertigo—Doxorubicin—thyroid cancer	0.00051	0.00289	CcSEcCtD
Agomelatine—Infection—Epirubicin—thyroid cancer	0.000498	0.00281	CcSEcCtD
Agomelatine—HTR2B—GPCR ligand binding—CALCB—thyroid cancer	0.000497	0.00897	CbGpPWpGaD
Agomelatine—Nervous system disorder—Epirubicin—thyroid cancer	0.000491	0.00278	CcSEcCtD
Agomelatine—Skin disorder—Epirubicin—thyroid cancer	0.000487	0.00275	CcSEcCtD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—thyroid cancer	0.000485	0.00875	CbGpPWpGaD
Agomelatine—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000485	0.00875	CbGpPWpGaD
Agomelatine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000484	0.00274	CcSEcCtD
Agomelatine—Anxiety—Doxorubicin—thyroid cancer	0.000482	0.00272	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00048	0.00272	CcSEcCtD
Agomelatine—Dry mouth—Doxorubicin—thyroid cancer	0.000473	0.00267	CcSEcCtD
Agomelatine—MTNR1B—Signaling Pathways—CALCB—thyroid cancer	0.000467	0.00842	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CALCB—thyroid cancer	0.000467	0.00842	CbGpPWpGaD
Agomelatine—Infection—Doxorubicin—thyroid cancer	0.000461	0.0026	CcSEcCtD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—KRAS—thyroid cancer	0.00046	0.00831	CbGpPWpGaD
Agomelatine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000455	0.00257	CcSEcCtD
Agomelatine—Insomnia—Epirubicin—thyroid cancer	0.000453	0.00256	CcSEcCtD
Agomelatine—Skin disorder—Doxorubicin—thyroid cancer	0.00045	0.00255	CcSEcCtD
Agomelatine—Paraesthesia—Epirubicin—thyroid cancer	0.00045	0.00254	CcSEcCtD
Agomelatine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000448	0.00253	CcSEcCtD
Agomelatine—Somnolence—Epirubicin—thyroid cancer	0.000446	0.00252	CcSEcCtD
Agomelatine—MTNR1B—Signaling Pathways—TRIM33—thyroid cancer	0.000442	0.00798	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TRIM33—thyroid cancer	0.000442	0.00798	CbGpPWpGaD
Agomelatine—Dyspepsia—Epirubicin—thyroid cancer	0.000441	0.00249	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000433	0.00245	CcSEcCtD
Agomelatine—Fatigue—Epirubicin—thyroid cancer	0.000432	0.00244	CcSEcCtD
Agomelatine—Constipation—Epirubicin—thyroid cancer	0.000429	0.00242	CcSEcCtD
Agomelatine—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000428	0.00772	CbGpPWpGaD
Agomelatine—Insomnia—Doxorubicin—thyroid cancer	0.000419	0.00237	CcSEcCtD
Agomelatine—Paraesthesia—Doxorubicin—thyroid cancer	0.000416	0.00235	CcSEcCtD
Agomelatine—Somnolence—Doxorubicin—thyroid cancer	0.000412	0.00233	CcSEcCtD
Agomelatine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00041	0.00232	CcSEcCtD
Agomelatine—Dyspepsia—Doxorubicin—thyroid cancer	0.000408	0.00231	CcSEcCtD
Agomelatine—MTNR1A—GPCR downstream signaling—TSHR—thyroid cancer	0.000403	0.00727	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—TSHR—thyroid cancer	0.000403	0.00727	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—CALCB—thyroid cancer	0.000401	0.00723	CbGpPWpGaD
Agomelatine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.0004	0.00226	CcSEcCtD
Agomelatine—Fatigue—Doxorubicin—thyroid cancer	0.0004	0.00226	CcSEcCtD
Agomelatine—Urticaria—Epirubicin—thyroid cancer	0.000398	0.00225	CcSEcCtD
Agomelatine—Constipation—Doxorubicin—thyroid cancer	0.000397	0.00224	CcSEcCtD
Agomelatine—Abdominal pain—Epirubicin—thyroid cancer	0.000396	0.00224	CcSEcCtD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—thyroid cancer	0.000391	0.00706	CbGpPWpGaD
Agomelatine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000379	0.00214	CcSEcCtD
Agomelatine—Urticaria—Doxorubicin—thyroid cancer	0.000368	0.00208	CcSEcCtD
Agomelatine—Abdominal pain—Doxorubicin—thyroid cancer	0.000367	0.00207	CcSEcCtD
Agomelatine—MTNR1A—Signaling by GPCR—TSHR—thyroid cancer	0.000366	0.0066	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—TSHR—thyroid cancer	0.000366	0.0066	CbGpPWpGaD
Agomelatine—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.000366	0.0066	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—PTEN—thyroid cancer	0.000363	0.00656	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—PTEN—thyroid cancer	0.000363	0.00656	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00036	0.00649	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00036	0.00649	CbGpPWpGaD
Agomelatine—Asthenia—Epirubicin—thyroid cancer	0.00036	0.00203	CcSEcCtD
Agomelatine—Pruritus—Epirubicin—thyroid cancer	0.000355	0.002	CcSEcCtD
Agomelatine—Diarrhoea—Epirubicin—thyroid cancer	0.000343	0.00194	CcSEcCtD
Agomelatine—Asthenia—Doxorubicin—thyroid cancer	0.000333	0.00188	CcSEcCtD
Agomelatine—Dizziness—Epirubicin—thyroid cancer	0.000331	0.00187	CcSEcCtD
Agomelatine—Pruritus—Doxorubicin—thyroid cancer	0.000328	0.00185	CcSEcCtD
Agomelatine—Vomiting—Epirubicin—thyroid cancer	0.000319	0.0018	CcSEcCtD
Agomelatine—Diarrhoea—Doxorubicin—thyroid cancer	0.000317	0.00179	CcSEcCtD
Agomelatine—Headache—Epirubicin—thyroid cancer	0.000314	0.00177	CcSEcCtD
Agomelatine—MTNR1A—GPCR downstream signaling—SST—thyroid cancer	0.000313	0.00565	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—SST—thyroid cancer	0.000313	0.00565	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PTCH1—thyroid cancer	0.000311	0.00561	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—PTCH1—thyroid cancer	0.000311	0.00561	CbGpPWpGaD
Agomelatine—Dizziness—Doxorubicin—thyroid cancer	0.000307	0.00173	CcSEcCtD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000302	0.00545	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—CALCA—thyroid cancer	0.000301	0.00544	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—CALCA—thyroid cancer	0.000301	0.00544	CbGpPWpGaD
Agomelatine—Nausea—Epirubicin—thyroid cancer	0.000298	0.00168	CcSEcCtD
Agomelatine—MTNR1B—Signaling Pathways—TCF7L1—thyroid cancer	0.000295	0.00533	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TCF7L1—thyroid cancer	0.000295	0.00533	CbGpPWpGaD
Agomelatine—Vomiting—Doxorubicin—thyroid cancer	0.000295	0.00167	CcSEcCtD
Agomelatine—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000293	0.00529	CbGpPWpGaD
Agomelatine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000292	0.00526	CbGpPWpGaD
Agomelatine—Headache—Doxorubicin—thyroid cancer	0.00029	0.00164	CcSEcCtD
Agomelatine—MTNR1A—Signaling by GPCR—SST—thyroid cancer	0.000284	0.00513	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—SST—thyroid cancer	0.000284	0.00513	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—CALCB—thyroid cancer	0.000281	0.00507	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000276	0.00499	CbGpPWpGaD
Agomelatine—Nausea—Doxorubicin—thyroid cancer	0.000275	0.00156	CcSEcCtD
Agomelatine—MTNR1B—Signaling by GPCR—CALCA—thyroid cancer	0.000274	0.00494	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—CALCA—thyroid cancer	0.000274	0.00494	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—CALCB—thyroid cancer	0.000255	0.0046	CbGpPWpGaD
Agomelatine—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000251	0.00452	CbGpPWpGaD
Agomelatine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000249	0.0045	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—TP53—thyroid cancer	0.000248	0.00447	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—TP53—thyroid cancer	0.000248	0.00447	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—CDK1—thyroid cancer	0.000248	0.00447	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—CDK1—thyroid cancer	0.000248	0.00447	CbGpPWpGaD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000244	0.0044	CbGpPWpGaD
Agomelatine—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000238	0.00429	CbGpPWpGaD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000235	0.00424	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—TSHR—thyroid cancer	0.00023	0.00415	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—CALCB—thyroid cancer	0.000227	0.00409	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000223	0.00402	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TSHR—thyroid cancer	0.000216	0.0039	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TSHR—thyroid cancer	0.000216	0.0039	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000213	0.00383	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PRKAR1A—thyroid cancer	0.000213	0.00383	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CALCB—thyroid cancer	0.000206	0.00371	CbGpPWpGaD
Agomelatine—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000203	0.00367	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MEN1—thyroid cancer	0.000203	0.00366	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MEN1—thyroid cancer	0.000203	0.00366	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—PTCH1—thyroid cancer	0.000196	0.00353	CbGpPWpGaD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00019	0.00342	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—TSHR—thyroid cancer	0.000186	0.00335	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTCH1—thyroid cancer	0.000184	0.00331	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTCH1—thyroid cancer	0.000184	0.00331	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—SST—thyroid cancer	0.000179	0.00323	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—CALCA—thyroid cancer	0.000172	0.00311	CbGpPWpGaD
Agomelatine—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000169	0.00304	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—SST—thyroid cancer	0.000168	0.00303	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—SST—thyroid cancer	0.000168	0.00303	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CALCA—thyroid cancer	0.000162	0.00292	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CALCA—thyroid cancer	0.000162	0.00292	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—PTCH1—thyroid cancer	0.000158	0.00285	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000154	0.00278	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CALCB—thyroid cancer	0.000151	0.00272	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CDK1—thyroid cancer	0.000146	0.00264	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CDK1—thyroid cancer	0.000146	0.00264	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—SST—thyroid cancer	0.000144	0.0026	CbGpPWpGaD
Agomelatine—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000144	0.0026	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TRIM33—thyroid cancer	0.000143	0.00258	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—CALCA—thyroid cancer	0.000139	0.00251	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000134	0.00242	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—TSHR—thyroid cancer	0.00013	0.00235	CbGpPWpGaD
Agomelatine—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000126	0.00228	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CALCB—thyroid cancer	0.000122	0.00219	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.00012	0.00216	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—TSHR—thyroid cancer	0.000118	0.00213	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NRG1—thyroid cancer	0.000118	0.00212	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NRG1—thyroid cancer	0.000118	0.00212	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000116	0.0021	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TRIM33—thyroid cancer	0.000115	0.00208	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000115	0.00207	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—RXRA—thyroid cancer	0.000108	0.00195	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TERT—thyroid cancer	0.000106	0.0019	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TERT—thyroid cancer	0.000106	0.0019	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—TSHR—thyroid cancer	0.000105	0.00189	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000103	0.00186	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—SST—thyroid cancer	0.000101	0.00182	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—HIF1A—thyroid cancer	0.000101	0.00182	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—HIF1A—thyroid cancer	0.000101	0.00182	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PTCH1—thyroid cancer	0.0001	0.00181	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	9.92e-05	0.00179	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—CALCA—thyroid cancer	9.73e-05	0.00176	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TCF7L1—thyroid cancer	9.53e-05	0.00172	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—TSHR—thyroid cancer	9.52e-05	0.00172	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PRKAR1A—thyroid cancer	9.37e-05	0.00169	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—MINPP1—thyroid cancer	9.28e-05	0.00167	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—SST—thyroid cancer	9.18e-05	0.00166	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—NRAS—thyroid cancer	8.89e-05	0.0016	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—NRAS—thyroid cancer	8.89e-05	0.0016	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—CALCA—thyroid cancer	8.84e-05	0.00159	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	8.76e-05	0.00158	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	8.53e-05	0.00154	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—BRAF—thyroid cancer	8.36e-05	0.00151	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—BRAF—thyroid cancer	8.36e-05	0.00151	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—SST—thyroid cancer	8.16e-05	0.00147	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PTCH1—thyroid cancer	8.1e-05	0.00146	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	8e-05	0.00144	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—CDK1—thyroid cancer	8e-05	0.00144	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MINPP1—thyroid cancer	7.93e-05	0.00143	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NDUFA13—thyroid cancer	7.89e-05	0.00142	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—CALCA—thyroid cancer	7.85e-05	0.00142	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TCF7L1—thyroid cancer	7.69e-05	0.00139	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—KRAS—thyroid cancer	7.65e-05	0.00138	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—KRAS—thyroid cancer	7.65e-05	0.00138	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CHST14—thyroid cancer	7.42e-05	0.00134	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—SST—thyroid cancer	7.41e-05	0.00134	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	7.25e-05	0.00131	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CALCA—thyroid cancer	7.13e-05	0.00129	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TSHR—thyroid cancer	6.97e-05	0.00126	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	6.89e-05	0.00124	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PRKAR1A—thyroid cancer	6.86e-05	0.00124	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NDUFA13—thyroid cancer	6.74e-05	0.00122	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MEN1—thyroid cancer	6.56e-05	0.00118	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—HRAS—thyroid cancer	6.5e-05	0.00117	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—HRAS—thyroid cancer	6.5e-05	0.00117	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CDK1—thyroid cancer	6.45e-05	0.00116	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CHST14—thyroid cancer	6.34e-05	0.00114	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—AKT1—thyroid cancer	6.32e-05	0.00114	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—AKT1—thyroid cancer	6.32e-05	0.00114	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CCND1—thyroid cancer	6.1e-05	0.0011	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CCND1—thyroid cancer	6.1e-05	0.0011	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HPGD—thyroid cancer	5.98e-05	0.00108	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTCH1—thyroid cancer	5.93e-05	0.00107	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTEN—thyroid cancer	5.89e-05	0.00106	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTEN—thyroid cancer	5.89e-05	0.00106	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	5.85e-05	0.00106	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—AKT1—thyroid cancer	5.74e-05	0.00104	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—AKT1—thyroid cancer	5.74e-05	0.00104	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TSHR—thyroid cancer	5.63e-05	0.00102	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PRKAR1A—thyroid cancer	5.54e-05	0.000999	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SST—thyroid cancer	5.42e-05	0.000979	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MEN1—thyroid cancer	5.29e-05	0.000954	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NRAS—thyroid cancer	5.25e-05	0.000947	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NRAS—thyroid cancer	5.25e-05	0.000947	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CALCA—thyroid cancer	5.22e-05	0.000942	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HPGD—thyroid cancer	5.11e-05	0.000922	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.85e-05	0.000875	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTCH1—thyroid cancer	4.78e-05	0.000863	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDK1—thyroid cancer	4.73e-05	0.000853	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—KRAS—thyroid cancer	4.52e-05	0.000815	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—KRAS—thyroid cancer	4.52e-05	0.000815	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SST—thyroid cancer	4.38e-05	0.000789	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CALCA—thyroid cancer	4.21e-05	0.00076	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.14e-05	0.000748	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TP53—thyroid cancer	4.02e-05	0.000725	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TP53—thyroid cancer	4.02e-05	0.000725	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—HRAS—thyroid cancer	3.84e-05	0.000693	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—HRAS—thyroid cancer	3.84e-05	0.000693	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDK1—thyroid cancer	3.81e-05	0.000688	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NRG1—thyroid cancer	3.79e-05	0.000684	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TPR—thyroid cancer	3.43e-05	0.00062	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TERT—thyroid cancer	3.41e-05	0.000614	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—AKT1—thyroid cancer	3.39e-05	0.000612	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—AKT1—thyroid cancer	3.39e-05	0.000612	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	3.38e-05	0.00061	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HIF1A—thyroid cancer	3.26e-05	0.000588	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.06e-05	0.000552	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NRG1—thyroid cancer	3.06e-05	0.000552	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TPR—thyroid cancer	2.93e-05	0.000529	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	2.89e-05	0.000521	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—NRAS—thyroid cancer	2.87e-05	0.000518	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TERT—thyroid cancer	2.75e-05	0.000496	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—BRAF—thyroid cancer	2.7e-05	0.000487	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HIF1A—thyroid cancer	2.63e-05	0.000474	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.62e-05	0.000472	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC5A5—thyroid cancer	2.57e-05	0.000464	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KRAS—thyroid cancer	2.47e-05	0.000446	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.41e-05	0.000435	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—NRAS—thyroid cancer	2.31e-05	0.000418	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC5A5—thyroid cancer	2.2e-05	0.000396	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—BRAF—thyroid cancer	2.18e-05	0.000393	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—RXRA—thyroid cancer	2.16e-05	0.00039	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.1e-05	0.000379	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HRAS—thyroid cancer	2.1e-05	0.000379	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.06e-05	0.000371	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—AKT1—thyroid cancer	2.04e-05	0.000368	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	1.99e-05	0.000359	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCND1—thyroid cancer	1.97e-05	0.000355	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTEN—thyroid cancer	1.9e-05	0.000343	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—AKT1—thyroid cancer	1.85e-05	0.000334	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—RXRA—thyroid cancer	1.85e-05	0.000333	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.8e-05	0.000324	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NRAS—thyroid cancer	1.7e-05	0.000306	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	1.69e-05	0.000306	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	1.65e-05	0.000297	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCND1—thyroid cancer	1.59e-05	0.000287	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTEN—thyroid cancer	1.53e-05	0.000277	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	1.5e-05	0.00027	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KRAS—thyroid cancer	1.46e-05	0.000263	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NRAS—thyroid cancer	1.37e-05	0.000247	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPARG—thyroid cancer	1.36e-05	0.000246	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—thyroid cancer	1.3e-05	0.000234	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HRAS—thyroid cancer	1.24e-05	0.000224	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KRAS—thyroid cancer	1.18e-05	0.000212	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPARG—thyroid cancer	1.17e-05	0.00021	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT1—thyroid cancer	1.09e-05	0.000198	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTGS2—thyroid cancer	1.07e-05	0.000194	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—thyroid cancer	1.05e-05	0.000189	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HRAS—thyroid cancer	1e-05	0.000181	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTEN—thyroid cancer	9.36e-06	0.000169	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTGS2—thyroid cancer	9.17e-06	0.000165	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT1—thyroid cancer	8.83e-06	0.000159	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTEN—thyroid cancer	7.99e-06	0.000144	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKT1—thyroid cancer	5.39e-06	9.73e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKT1—thyroid cancer	4.61e-06	8.31e-05	CbGpPWpGaD
